Compare Stocks

→ World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPIX ESSA Pharma	$6.12 -2.1%	$8.32	$2.56 ▼ $11.67	$270.75M	1.62	135,637 shs	64,765 shs
KMPH Zevra Therapeutics		$5.51	$4.00 ▼ $6.92	$200.47M	2.16	189,500 shs	64,100 shs
MACK Merrimack Pharmaceuticals	$14.73 +0.1%	$14.71	$11.53 ▼ $15.89	$214.03M	1.43	110,789 shs	82,841 shs
SMMT Summit Therapeutics	$3.55 -1.1%	$4.08	$1.30 ▼ $5.22	$2.49B	-1.21	2.18 million shs	1.41 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPIX ESSA Pharma	-2.34%	-11.60%	-30.86%	-8.09%	+133.21%
KMPH Zevra Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
MACK Merrimack Pharmaceuticals	-0.14%	+0.20%	-0.14%	+10.60%	+21.57%
SMMT Summit Therapeutics	-3.75%	+0.56%	+9.45%	-21.10%	+163.97%

AI finds its first serious application (Ad)

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EPIX ESSA Pharma	1.6855 of 5 stars	3.5	3.0	0.0	0.0	0.0	3.3	0.0
KMPH Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	1.47 of 5 stars	3.5	0.0	0.0	0.0	2.4	3.3	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPIX ESSA Pharma	3.00	Buy	$16.50	169.61% Upside
KMPH Zevra Therapeutics	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	3.00	Buy	$8.00	125.35% Upside

Current Analyst Ratings

Latest EPIX, SMMT, KMPH, and MACK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/26/2024	SMMT Summit Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$3.30 per share	N/A
KMPH Zevra Therapeutics	$10.72M	0.00	N/A	23.28	$3.63 per share	0.00
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
SMMT Summit Therapeutics	$700K	3,558.62	N/A	N/A	$0.11 per share	32.27

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPIX ESSA Pharma	-$26.58M	-$0.59	N/A	N/A	N/A	N/A	-17.41%	-17.04%	5/14/2024 (Estimated)
KMPH Zevra Therapeutics	-$8.56M	N/A	0.00	N/A	N/A	-328.56%	-16.12%	-14.17%	N/A
MACK Merrimack Pharmaceuticals	-$1.18M	-$0.08	N/A	∞	N/A	N/A	-6.24%	-6.09%	5/2/2024 (Estimated)
SMMT Summit Therapeutics	-$614.93M	-$1.53	N/A	N/A	N/A	N/A	-87.45%	-41.17%	5/1/2024 (Confirmed)

Latest EPIX, SMMT, KMPH, and MACK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2024	N/A	SMMT Summit Therapeutics	-$0.06	N/A	+$0.06	N/A	N/A	N/A
3/7/2024	Q4 2023	MACK Merrimack Pharmaceuticals	N/A	-$0.01	-$0.01	-$0.01	N/A	N/A
2/20/2024	Q4 2023	SMMT Summit Therapeutics	N/A	-$0.05	-$0.05	-$0.05	N/A	$0.20 million
2/13/2024	12/31/2023	EPIX ESSA Pharma	-$0.17	-$0.14	+$0.03	-$0.14	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
KMPH Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPIX ESSA Pharma	N/A	40.74	40.74
KMPH Zevra Therapeutics	0.14	10.10	10.10
MACK Merrimack Pharmaceuticals	N/A	43.50	43.50
SMMT Summit Therapeutics	1.29	9.30	9.30

Ownership

Institutional Ownership

Company	Institutional Ownership
EPIX ESSA Pharma	75.12%
KMPH Zevra Therapeutics	19.39%
MACK Merrimack Pharmaceuticals	63.97%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
EPIX ESSA Pharma	14.70%
KMPH Zevra Therapeutics	1.10%
MACK Merrimack Pharmaceuticals	28.87%
SMMT Summit Therapeutics	83.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
EPIX ESSA Pharma	50	44.24 million	37.74 million	Optionable
KMPH Zevra Therapeutics	22	34.51 million	34.13 million	Optionable
MACK Merrimack Pharmaceuticals	426	14.53 million	10.34 million	Optionable
SMMT Summit Therapeutics	105	701.70 million	114.38 million	Optionable

EPIX, SMMT, KMPH, and MACK Headlines

Source	Headline
	Summit Therapeutics (SMMT) Scheduled to Post Quarterly Earnings on Wednesday marketbeat.com - April 25 at 11:45 AM
	Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 businesswire.com - April 24 at 4:30 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Up 10.6% marketbeat.com - April 23 at 3:43 PM
	Summit Therapeutics (NASDAQ:SMMT) Stock Crosses Below Fifty Day Moving Average of $4.14 americanbankingnews.com - April 23 at 5:34 AM
	Short Interest in Summit Therapeutics Inc. (NASDAQ:SMMT) Rises By 28.6% americanbankingnews.com - April 15 at 5:40 AM
	Short Interest in Summit Therapeutics Inc. (NASDAQ:SMMT) Grows By 28.6% marketbeat.com - April 13 at 7:47 PM
	Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.7% marketbeat.com - April 12 at 3:59 PM
	Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors finance.yahoo.com - April 11 at 5:11 PM
	Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors businesswire.com - April 11 at 4:30 PM
	Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum businesswire.com - April 10 at 7:00 AM
	Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor reuters.com - April 9 at 4:33 PM
	Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer prnewswire.com - April 9 at 4:05 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $3.95 marketbeat.com - April 4 at 2:02 PM
	Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6% marketbeat.com - April 1 at 4:50 PM
	Summit Therapeutics CEO acquires shares worth over $411k investing.com - March 29 at 8:13 PM
	Why Summit Therapeutics Stock Crushed the Market This Week fool.com - March 29 at 5:43 PM
	Insider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Acquires 30,000 Shares of Stock insidertrades.com - March 29 at 7:14 AM
	Summit Therapeutics (NASDAQ:SMMT) Trading 18.9% Higher After Insider Buying Activity marketbeat.com - March 28 at 10:31 AM
	Insider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Buys 30,000 Shares of Stock marketbeat.com - March 27 at 9:29 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $3.28 marketbeat.com - March 26 at 12:25 PM
	Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 businesswire.com - March 14 at 7:00 AM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT prnewswire.com - March 11 at 6:05 PM
	Shareholders that lost money on Summit Therapeutics Inc. (SMMT) should contact Levi & Korsinsky about Securities Fraud Investigation - SMMT accesswire.com - March 6 at 4:40 AM
	Lost Money on Summit Therapeutics Inc.(SMMT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation accesswire.com - March 6 at 4:35 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ESSA Pharma

NASDAQ:EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Zevra Therapeutics

NASDAQ:KMPH

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Merrimack Pharmaceuticals

NASDAQ:MACK

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Summit Therapeutics

NASDAQ:SMMT

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial